Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 13, 2006

View Archived Issues

Weekly DN-101 administration assessed in cancer patients

In vitro studies reveal effects of pirfenidone alone and with IFN-gamma-1B

Lestaurtinib, midostaurin cytotoxic in acute myeloid leukemia blasts

Novel anti-HLA-DR antibody may potentiate rituximab's antilymphoma activity

P. falciparum methionine aminopeptidase 1: novel target for antimalarial drugs

Small MRP1 inhibitor sensitizes resistant neuroblastoma tumors to chemotherapy

ADC-4022 for COPD and asthma enters clinic

Rivaroxaban phase III program outlined in stroke prevention and VTE

KB-002 studied in rheumatoid arthritis patients

ACR-325 enters clinic for treatment of psychosis

3M to sell global branded pharmaceuticals business

MedImmune files IND for cell culture-based influenza vaccine

MedImmune to sell CytoGam to ZLB Behring

Pozen submits full response to Trexima approvable letter

Phase IIb study evaluates AN-0128 in children with atopic dermatitis

Cardiovascular outcomes study not required for naproxcinod

UCB publishes offer document for takeover of Schwarz Pharma

IND filing for CollaRx Gentamicin in diabetic foot ulcers

GlycoPEG-GCSF studied in phase I trial

ARQ-501 demonstrates tolerability and signs of antitumor activity

Neurobiological Technologies makes case for Viprinex in stroke

Prochymal shows good complete response rate in GVHD

Recent patents describe novel antidiabetic agents

Novel cannabinoid CB1 receptor antagonists emerge from Pfizer R&D

Recent patents describe new compounds for thrombotic disorders

SLV-308 shows potential for concomitant treatment of parkinsonian symptoms

Lacosamide could be useful in essential tremor, dyskinetic side effects secondary to antipsychotics

AMPA receptor antagonist E-2007 shows positive effects as adjunct therapy to levodopa

Genentech to acquire Tanox

Mexican approval for Acomplia

Mirapex approved for restless legs syndrome

Presurgical bevacizumab/erlotinib safe and effective in RCC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...